The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future

(چکیده مقاله) :
Abstract :

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease.
SARS-CoV-2 infects human cells via the binding of its S protein to the receptor
angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors)
regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2
expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some
professional groups are concerned about whether the use of RAAS inhibitors affects
the risk of SARS-CoV-2 infection or the risk of severe illness and mortality in
COVID-19 patients. In this review, we summarize preclinical and clinical studies to
investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or
patients. We also analyzed whether the use of these drugs affects the risk of
SARS-CoV-2 infection, severe illness or mortality based on recent studies. Finally,
the review suggests that current evidence does not support the concerns.

(توضیحات تکمیلی) :

(توضیحات تکمیلی) :
Description :

مقاله ISI انگلیسی اصلی
سال انتشار: 2020
فایل ISI انگلیسی اصلی ، با فرمت Pdf
تعداد صفحات فایل ISI انگلیسی اصلی: 35 صفحه

Authors / Descriptions(نویسندگان/توضیحات): سال انتشار 2020 \ مقاله ISI انگلیسی اصلی \ نویسندگان: Jishou Zhang, Menglong Wang, Wen Ding, Jun Wan
Sent date(تاریخ ارسال) : 1399/05/03  |   7/24/2020
Number of visits(تعداد بازدید): 724
Key words (کلمات کلیدی): COVID-19; SARS-CoV-2; RAAS inhibitor; ACE2
Number of pages(تعداد صفحات) : 35
نظرات کاربران در مورد این آگهی
در حال حاضر هیچ نظری ثبت نگردیده است .
ارسال پیام

مقالات مرتبط